Document is current

Article History

Received: 2 August 2024

Accepted: 11 November 2024

First Online: 27 November 2024

Declarations

:

: The study was approved by the Ethics Committee of the Innsbruck Medical University (reference numbers: AN2015-0038 346/4.17; 1054/2019) and conducted in accordance with the Declaration of Helsinki Principles

: Not applicable.

: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. However, the following authors receive financial support for the specified activities: KL reports travel expenses from GSK, Roche, Eisai and MSD. IT reports honoraria from Roche and Astra Zeneca; travel expenses from Eisai, GSK, PharmaMar, Roche, Astra Zeneca, Pfizer; participation on advisory boards from Astra Zeneca. VW reports honoraria from Roche, Novartis; travel expenses from Roche; participation on advisory boards from Novartis. CM reports consulting fees from Roche, Novartis, Amgen, MSD, PharmaMar, Astra Zeneca, GSK, Seagen; honoraria from Roche, Novartis, Amgen, MSD, PharmaMar, Astra Zeneca, GSK, Seagen; travel expenses from Roche, Astra Zeneca; participation on advisory boards from Roche, Novartis, Amgen, MSD, Astra Zeneca, Pfizer, PharmaMar, GSK, Seagen. AGZ reports consulting fees from Amgen, Astra Zeneca, GSK, MSD, Novartis, PharmaMar, Roche-Diagnostics, Seagen; honoraria from Amgen, Astra Zeneca, GSK, MSD, Novartis, PharmaMar, Roche, Seagen; travel expenses from Astra Zeneca, Gilead, Roche; participation on advisory boards from Amgen, Astra Zeneca, GSK, MSD, Novartis, Pfizer, PharmaMar, Roche, Seagen.